Share to
Anti-Payload—MMAE/MMAF Antibody
Email:
htm0086@vip.163.com
Still deciding? Let’s start with a sample.Contact us!
Category
- Description
-
Product Background Overview
Antibody-drug conjugates (ADCs) are an emerging class of targeted therapies for cancer treatment, designed to deliver Small-molecule chemical drugs (Payload) is directly delivered to and kills tumor cells; ADCs are essentially targeted chemotherapeutic agents that have now advanced to the third generation, with significantly improved safety and efficacy, and further technological innovations are increasingly focused on In areas such as the payload, linker, and conjugation technologies, the modification and optimization of the payload have consistently been a key focus in ADC development.
The second-generation payloads are primarily tubulin inhibitors. These agents disrupt mitosis; since tumor cells divide more rapidly than most normal cells, tubulin inhibitors are particularly effective at killing cancer cells. Tubulin inhibitors can be classified into two types: one type promotes tubulin polymerization, leading to unregulated microtubule growth, such as MMAE and MMAF, derivatives of tetrodotoxin ; the 14 approved ADC drug Among them, six ADC drugs use tetrodotoxin-derived payloads, accounting for nearly 50% of the total; moreover, more than 80 pipeline projects currently under development employ MMAE as the payload, making tetrodotoxin derivatives the most commonly used payload to date. Another class of agents that effectively inhibits microtubule assembly and induces mitotic arrest in cells includes, for example, Meidengsu Derivatives such as DM1 and DM4.
Third-generation payload DNA inhibitors can disrupt DNA structure and function through mechanisms such as double-strand breaks, alkylation, intercalation, cross-linking, and inhibition of topoisomerase I (TOPO1), thereby promoting cancer cell death. DNA inhibitors are further classified into DNA-damaging agents and topoisomerase I inhibitors. DNA-damaging agents include calicheamicins, PBD (Pyrrolo[3,2-b]benzodiazepine) derivatives, bleomycin derivatives, and others. Topoisomerase I inhibitors are primarily camptothecin derivatives, including irinotecan, SN38, and DXD. Topoisomerase I facilitates the completion of DNA Topological structure Its expression level is significantly higher in tumor cells than in normal cells; topoisomerase I inhibitors induce cell death by trapping the topoisomerase I–DNA cleavage complex.
To support ADC pharmacokinetic analysis, Heyou Sheng Bio has launched several anti-payload antibodies; Hycells’ Anti-Payload antibodies feature High specificity, high stability, and high sensitivity These characteristics can be leveraged for plasma/serum pharmacokinetic analysis of ADC drugs, determination of drug-binding affinity, DAR value analysis, and evaluation of ADC efficacy, thereby accelerating the ADC drug development process and providing a basis for preclinical application and dose optimization.
MMAE MMAF antibody Antibody Validation Data Display
★ MMAE Monoclonal Antibody Binding Activity Assay
For more details on HeYouSheng Bio’s payload antibodies, please contact our sales representative. Scan the QR code below to request a free trial sample.
Contact: Mr. Xie 15201775322 。
Related document downloads:
Consult Now
Please note: Kindly provide your contact information, and our dedicated professionals will get in touch with you as soon as possible!
